Endo International announced the completion of the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation for $25 million including additional payments upon the achievement of certain regulatory and sales milestones.
Endo will collaborate with Trimel on all regulatory and clinical development activities regarding Natesto, which was approved by the US Food and Drug Administration (FDA) in May of 2014. Endo intends to launch the product, through its Endo Pharmaceuticals subsidiary, in the first quarter of 2015.
Natesto is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including:Primary hypogonadism (congenital or acquired), Hypogonadotropic hypogonadism (congenital or acquired).